Scott Nelson Live

In this episode, we sat down with Paul Coletta, the co-founder and CEO of Vero Bioscience. Vero's OrganAge™ assay measures the biological age of each organ from a single blood draw, and its Vero Compass platform turns that reading into a targeted action plan. Paul built his career on storytelling and consumer marketing, starting with a decade at Disney before leading brand and product marketing roles at MTV Networks, Nickelodeon, and Hewlett-Packard. He then went on to build popular food brands including Jamba Juice and Pinkberry, and spent a decade as CEO and Chairman of Urban Remedy. In this interview, Paul explains why scientific validation isn't enough to bring a diagnostic to market. He also shares how Vero closed a $6 million seed round in just three weeks, what "patriots, not mercenaries" means when building a team, and the difference between asking a board for advice versus asking for permission. If you'd rather read the summary of Paul’s episode, head over here.

In this episode, we sat down with Deanna Harshbarger, CEO of Cala Health. Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor. Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care. In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.

In this episode, we sat down with Michael Mangano, President and CEO of ABK Biomedical. ABK’s Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer. Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million. In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.

In this episode, we sat down with we sat down with Murthy Simhambhatla, CEO of SetPoint Medical. SetPoint is commercializing the first FDA-approved neuroimmune modulation implant for rheumatoid arthritis. Previously, Murthy was CEO of Evolus, leading the company through its IPO, and held multiple leadership roles at Abbott, including President of Abbott Medical Optics and head of the company's Ibis Biosciences molecular diagnostics business. Earlier in his career, Murthy led development of Abbott's XIENCE drug-eluting stent platform following Abbott's acquisition of Guidant. Murthy holds a Ph.D. in Polymer Engineering and is a Fellow of the American Institute for Medical and Biological Engineering. In this interview, Murthy discusses building commercial conviction years before launch, how to sequence platform indications around adjacent markets, and why SetPoint built its reimbursement function in-house rather than outsourcing it.

In this episode, we sat down with David Veino, President and CEO of Neuros Medical. Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain. Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.